Grace Halsey

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not GLP-1 receptor agonists were on board at study baseline.

The much anticipated results from the SURPASS 2 clinical trial demonstrated reductions in A1c and body weight with tirzepatide that were significant and superior to those with semaglutide.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not SGLT2 inhibitors were on board at study baseline.

STEP program investigator Robert F. Kushner, MD, reviews the "unprecedented" clinical trial results for semaglutide 2.4 mg and speaks specifically to primary care clinicians treating obesity.

Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.

Leading international diabetes researchers and clinicians will use the ADA's 81st annual Scientific Sessions as an ideal classroom to examine pandemic impact on diverse populations with diabetes.

Review of more than 300 clinical trials with products purported to facilitate weight loss found wide variability in risk of bias and data sufficiency suggesting caution among patients and physicians.

The CDC term "post-COVID conditions" includes the wide range of physical and emotional sequelae affecting many patients for ≥4 weeks post-infection.

Adults in their 30s and 40s who had high BMI in adolescence were at highest risk for type 2 diabetes and early MI, regardless of adult BMI, after 24 years of follow-up, a new study finds.

The American Diabetes Association 2021 Scientific Sessions run from June 25 to 29. This short slide show highlights 6 clinical trial updates that are a "must see" for primary care clinicians.

MOBILE study lead author Tom Martens, MD, talks about the inherent benefits of CGM for T2D patients on basal insulin treated in primary care and also the challenges to this vision of patient care.

MOBILE study lead author Thomas W. Martens, MD, discusses results of the study which was designed to capture CGM results in real-world primary care practice.

The CDC has intensified surveillance of the Delta variant of SARS-CoV-2 which now accounts for 10% of new US COVID-19 infections.

Patients with T2D see significant improvement in glycemic control using continuous glucose monitoring. MOBILE study lead author Thomas W. Martens, MD, highlights the evidence.

A new study found that patients with severe obesity who had even one discussion about bariatric surgery with a clinician were more likely to lose weight but that the discussions are infrequent.

A new study challenges traditional criteria for patient selection for metabolic surgery, demonstrating significant weight loss and disease remission for those with BMI of 30-35.

The vaccine is indicated for prevention of invasive disease and pneumonia caused by 20 Streptococcus pneumoniae serotypes.

Analysis of NHANES data shows significant downturns in control of the 3 risk factors in patients with diabetes, which could mean population-level increases in related illness.

Poll: 91% of women don’t know heart disease is the #1 cause of death in women and 81% aren’t aware that the Pap test screens only for cervical cancer. Counseling and education are needed.

An Australian study of more than 7000 adults suggests 2 servings of whole fruit per day helps preserve insulin sensitivity and mitigate risk for type 2 diabetes.

The FDA approved today the first drug that targets the pathophysiolgic process responsible for Alzheimer disease and the first drug since 2003 to be approved for any Alzheimer treatment.

Semaglutide 2.4 mg is the first drug approved for chronic weight management since 2014 and the first once-weekly GLP-1 receptor agonist to be approved for that purpose.

MOBILE study group: in patients with type 2 diabetes on a less intensive insulin regimen, CGM use lowered A1c and increased time in target glucose range vs traditional blood glucose monitoring.

A new study reveals that nearly three-quarters of medication organizer packages contain a drug class from which a single pill could be lethal for a child.

Magnet technology in the iPhone 12 Pro Max that allows the device to charge wirelessly can significantly impair function of a variety of cardiac implantable electronic devices.

In people without diabetes and considered low risk for CVD, A1c was associated in a graded, positive fashion with subclinical atherosclerosis, even at prediabetes levels.

The landmark Diabetes Prevention Program (DPP) trial and follow-up studies proved that risk of T2D can be reduced in patients at high risk for the disease. Do you know by how much?

Four major cardiology organizations stand behind increased government action to eradicate tobacco use worldwide. Click here for a summary of why, why now, and how.

Adults with OCD were more than 3 times as likely to have an ischemic stroke after age 40 than those without the disorder, according to a study published in Stroke.

For patients with moderate-to-severe persistent asthma, new guidelines from the NAEPP recommend SMART, particularly for patients with a recent disease exacerbation.